Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Ping-Jen, Yu Ming-Lung, Chen Ming-Yao, Chen Chi-Yi, Kuo Hsing-Tao, Hung Chao-Hung, Tseng Kuo-Chih, Lai Hsueh-Chou, Peng Cheng-Yuan, Wang Jing-Houng, Chen Jyh-Jou, Lee Pei-Lun, Chien Rong-Nan, Yang Chi-Chieh, Lo Gin-Ho, Kao Jia-Horng, Liu Chun-Jen, Liu Chen-Hua, Yan Sheng-Lei, Lin Chun-Yen, Su Wei-Wen, Chu Cheng-Hsin, Chen Chih-Jen, Tung Shui-Yi, Tai Chi-Ming, Lin Chih-Wen, Lo Ching-Chu, Cheng Pin-Nan, Chiu Yen-Cheng, Wang Chia-Chi, Cheng Jin-Shiung, Tsai Wei-Lun, Lin Han-Chieh, Huang Yi-Hsiang, Yeh Ming-Lun, Huang Chung-Feng, Huang Jee-Fu, Dai Chia-Yen, Chung Wan-Long, Tsai Pei-Chien, Bair Ming-Jong, T-COACH Study Group
Аннотация
METHODS: This nationwide, real-world cohort included a total of 5550 patients with HCV infection who received IFN-based therapy between 2003 and 2014. The primary outcome was the incidence of new-onset depressive disorder. The cumulative incidence of depressive disorders was analyzed using Gray's competing risk method, and Cox proportional hazards models were used to identify independent risk factors.
RESULTS: During a mean follow-up of 4.07 years, the incidence of new-onset depression was 18.0 % in patients with SVR and 16.7 % in patients with non-SVR. Achieving SVR did not significantly reduce the risk of depression across the various subgroups. Multivariate analysis identified older age (≥45 years, HR = 1.32, 95 % CI: 1.10-1.57, P = 0.003) and female sex (HR = 1.29, 95 % CI: 1.11-1.49, P = 0.0007) as independent risk factors for depression, but only in patients with SVR.
CONCLUSION: Our findings highlight the need for long-term psychiatric monitoring in patients with HCV infection after treatment, particularly in high-risk subgroups. Further studies involving direct-acting antiviral-treated cohorts with extended follow-up periods are required to validate these findings.